Results 261 to 270 of about 140,143 (309)

ACE Inhibition in Diabetic Patients

PharmacoEconomics, 1996
Diabetic nephropathy is the inevitable long term complication of prolonged hyperglycaemia for up to 40% of patients with diabetes mellitus. Most patients with renal involvement have a number of comorbid conditions including hypertension, coronary artery disease. peripheral vascular disease and retinopathy.
R A, Rodby, E J, Lewis
openaire   +2 more sources

Renal Effects of ACE Inhibition in Ovine Heart Failure: A Comparison of Intermittent and Continuous ACE Inhibition

Journal of Cardiovascular Pharmacology, 1990
Results of uncontrolled studies suggest that the duration of action of an ACE inhibitor may be an important determinant of renal impairment when using these agents to treat patients with heart failure. To determine whether there is experimental evidence for this hypothesis, we compared the effects of intermittent (captopril, 25 mg i.v.
M A, Fitzpatrick, M T, Rademaker, C M, Frampton, E A, Espiner, T G, Yandle, G, A'Court, H, Ikram   +6 more
openaire   +2 more sources

ACE Inhibition in Hypertension

American Journal of Cardiovascular Drugs, 2007
Ongoing developments in our understanding of cardiovascular disease, together with the introduction of new drugs to treat these conditions, has led to much debate over the optimal management of hypertension. The ALLHAT study showed no major differences in cardiovascular outcome among three major classes of antihypertensive drugs.
openaire   +2 more sources

The Effects of ACE Inhibition on Progression of Atherosclerosis

Journal of Cardiovascular Pharmacology, 1993
Angiotensin-converting enzyme inhibitors have been extensively studied and established in the treatment of hypertension, heart failure, and ventricular dysfunction. They have various cardiac and vascular protective effects, but the relevant mechanisms of action in these areas remain to be fully understood.
openaire   +2 more sources

ACE inhibition in the tissues.

Clinical physiology and biochemistry, 1993
The discovery of the components of the renin angiotensin system (RAS) in various tissues gave rise to the idea that functional "tissue" renin-angiotensin systems exist that are more or less independent of the hormonal RAS. Further support to this notion came from the recent demonstration of the mRNA for the protein components of the RAS in a number of ...
T, Unger, P, Gohlke
openaire   +1 more source

Triple ACE-ECE-NEP Inhibition in Heart Failure: A Comparison With ACE and Dual ECE-NEP Inhibition

Journal of Cardiovascular Pharmacology, 2005
Abstract: Mortality remains high in chronic heart failure (CHF) because under ACE inhibitor treatment other neurohumoral systems remain/become (de)activated, such as the endothelin and atrial natriuretic peptide pathways.
Virginie, Mellin, Arco Y, Jeng, Christelle, Monteil, Sylvanie, Renet, Jean Paul, Henry, Christian, Thuillez, Paul, Mulder   +6 more
openaire   +2 more sources

ACE-Inhibition plus Mineralocorticoid Antagonism versus ACE-inhibition alone in Patients with Anterior Myocardial Infarction

Cardiovascular Drugs and Therapy, 2001
Aldosterone exerts pro-fibrotic effects, acting via mineralo-corticoid reeptors in cardiovascular tissues. Aldosterone antagonism in combination with ACE inhibition may better protect against untoward effects of aldosterone than ACE inhibition alone.In a double blind, randomised study the tolerability and efficacy of canreonate (25 mg/day) plus ...
P, Di Pasquale, S, Cannizzaro, A, Scandurra, A, Giubilato, S, Scalzo, S, Paterna   +5 more
openaire   +2 more sources

Differential Inhibition of Plasma Versus Tissue ACE by Utibapril: Biochemical and Functional Evidence for Inhibition of Vascular ACE Activity

Journal of Cardiovascular Pharmacology, 1997
Utibapril is an angiotensin-converting enzyme (ACE) inhibitor with a proposed tissue-specific inhibitory profile. This implies that at a certain dose, utibapril should be able to inhibit tissue ACE activity without affecting plasma ACE. Moreover, if tissue ACE activity is rate limiting, functional conversion of angiotensin I should be decreased ...
Buikema, H., Pinto, Y. M., van Geel, P. P., Rooks, G., de Langen, C. D., de Graeff, P. A., van Gilst, W. H.   +6 more
openaire   +3 more sources

Effects of ACE inhibition on the heart.

Journal of human hypertension, 1995
Inhibition of the angiotensin converting enzyme (ACE) results in suppression of the formation of angiotensin II and delay of the degradation of bradykinin. Hence, the pharmacological effects of ACE inhibitors are attributable to both of these mechanisms.
I, Gavras, A, Manolis, H, Gavras
openaire   +1 more source

Present and future of ACE inhibition

Trends in Pharmacological Sciences, 2002
ACE Inhibitorsedited by P. D'Orleans-Juste and G.E. Plante, Birkhauser Verlag, 2001. Euro119 (hardback) (x + 184 pages) ISBN 376435982XToday, blockers of the renin–angiotensin system are standard therapy for essential hypertension and congestive heart failure, and represent an important step in the management of patients with diabetic and non-diabetic ...
openaire   +1 more source